Program
ATG-201
A development code.
Its studies are mostly in Lupus Erythematosus, Systemic, led by Antengene Biologics.
Furthest: phase 1, since Jul 24, 20261 company-led study, 1 open or runningNext primary completion: Dec 1, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Antengene Biologics | 11 open or running | phase 1since Jul 24, 2026 | Jul 24, 2026 | Dec 1, 2028phase 1 · NCT07732309 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 24, 2026First study: phase 1 study in Lupus Erythematosus, SystemicFirst studyNCT07732309 · 149 planned · China
Ahead
- Dec 1, 2028Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07732309
TargetBeta
“ATG-201 is a recombinant, human IgG1-like TCE that simultaneously binds to human CD3 and CD19.”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| YK012rule | excyte-biopharma-ltd | phase 2 | 5 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978rule | cullinan-therapeutics-inc | phase 1 | 4 |
| Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rule | cytocares-inc | phase 1 | 4 |
| Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565 | Novartis | phase 1 | 3 |
| KT501rule | kali-therapeutics-inc | phase 1 | 1 |
| KT502rule | kali-therapeutics-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07732309Lupus Erythematosus, Systemic · China | 1 | Recruiting | Dec 1, 2028 | 149 |
How it is read
Names in the registry
- “ATG-201”, 1 entry
Codes read as this program: ATG201.
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.